Skip to main content

Drug Interactions between cytarabine liposomal / daunorubicin liposomal and Yonsa

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

DAUNOrubicin liposomal cytarabine liposomal

Applies to: cytarabine liposomal / daunorubicin liposomal and cytarabine liposomal / daunorubicin liposomal

Using DAUNOrubicin liposomal together with cytarabine liposomal or other chemotherapy drugs may increase the risk of side effects, especially those that affect the bone marrow or gastrointestinal tract. You may experience a greater number or more severe side effects such as nausea; vomiting; diarrhea; loss of appetite; mouth sores; abdominal pain; delayed wound healing; and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should seek medical attention if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. You may need a dose adjustment or more frequent monitoring by your doctor to safely use these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

DAUNOrubicin liposomal abiraterone

Applies to: cytarabine liposomal / daunorubicin liposomal and Yonsa (abiraterone)

Abiraterone may increase the blood levels of DAUNOrubicin liposomal. This can increase the risk of side effects such as irregular heartbeat, heart failure, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. Contact your doctor if you experience potential signs and symptoms of these conditions such as paleness, fatigue, dizziness, fainting, unusual bleeding or bruising, fever, chills, sore throat, body aches, or other flu-like symptoms. You should seek immediate medical attention if you experience sudden, unexplained weight gain; swelling of the hands, ankles, or feet; chest pain; or difficulty breathing, as these may be indications of heart failure. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Moderate

abiraterone food

Applies to: Yonsa (abiraterone)

Taking abiraterone with food increases the amount of medicine that gets absorbed by the body. This may increase the risk of side effects such as high blood pressure, water retention, and a condition called hypokalemia (low blood potassium), which in severe cases can lead to muscle weakness, paralysis, breathing and swallowing difficulties (due to muscle paralysis), and irregular heart rhythm. You should take abiraterone once a day on an empty stomach. No food should be eaten for at least two hours before and one hour after taking abiraterone. Let your doctor know if you experience nausea, vomiting, constipation, abdominal cramping, confusion, dizziness, lightheadedness, fainting, muscle weakness, muscle cramps, numbness or tingling, rapid heart beat, chest pain, and/or swelling in the legs or feet, as these may be symptoms of hypokalemia or excessive effects of abiraterone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer